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• Descriptive statistics will be performed to describe any 
differences in patients treated with eravacycline and those 
treated with best previously available therapy.
• Inferential statistics will include chi-square tests for nominal 
data, Mann-Whitney U test for non-parametric data, and 
Student’s t-test for parametric data. 
• The research results will provide data and patient outcomes 
on a particularly drug resistant pathogen, namely 
Acinetobacter baumannii. This will be the first report of its 
kind.
• Multi-center, retrospective, observational analysis 
• Data will be extracted from the electronic medical record of patients 
admitted to a Valley Health System hospital (n=6) between January 
2017 and December 2020
• The following data will be collected:
• Demographic variables: age, gender, ethnicity
• Date of hospital (and, if applicable ICU) admission and discharge
• Comorbidities: tracheostomy, CHF, COPD, diabetes, 
immunocompromised, and nursing home residence
• Type of pneumonia (community-, hospital-, or ventilator-
associated) 
• Index Acinetobacter baumannii culture type and susceptibility 
results including MICs
• Empiric and definitive antibiotic agents
• qSOFA score
• CURB-65 score
• Temperature, heart rate, and respiratory rate at the time of empiric 
antibiotic initiation and 14 days after definitive antibiotic initiation 
• WBCs and SCr at the time of empiric antibiotic initiation and 14 
days after definitive antibiotic initiation 
DATA ANALYSIS
• Eravacycline is a fluorocycline antibiotic within the 
tetracycline class, it inhibits bacterial protein synthesis by 
reversibly binding to the 30S ribosomal subunit.
• Eravacycline has a broad spectrum of activity, including 
activity against Acinetobacter baumannii, including multi-
drug resistant (MDR) strains. 
• There are currently no published studies documenting 
patient outcomes with the use of eravacycline against MDR 
Acinetobacter baumannii.
• Study Objective: To assess the efficacy of eravacycline 
use, in comparison to best previously available therapy, in 




• Primary Outcome: 30-day-in-hospital mortality
• Secondary Outcomes:
• Clinical cure at day 14 from definitive antibiotic 
initiation, defined as resolution of signs/symptoms of 
index infection or discharge to lower level of care
• Duration of hospital length of stay (LOS), ICU LOS
• Readmission within 90-days with a drug resistant 
Acinetobacter baumannii respiratory culture
• Microbiologic cure (if applicable), defined as 
respiratory culture negative for drug-resistant 
Acinetobacter baumannii during index hospitalization 
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Inclusion Criteria Exclusion Criteria
• Age ≥18 years old
• Pneumonia diagnosis – new 
radiologic finding on chest x-
ray and  receipt of systemic 
antibiotics pneumonia for ≥ 72 
hours
• Respiratory culture positive for 
drug-resistant Acinetobacter 
baumannii
• Respiratory culture positive for 
drug-resistant Acinetobacter 
baumannii within the previous 
30 days
